Tesamorelin
The only FDA-approved GHRH analog with proven efficacy for visceral fat reduction—uniquely selective for abdominal fat compartments.
Also known as: GHRH Analog, Egrifta, FDA-Approved
Available on Forge Amino
Tesamorelin 10MG — independently lab tested, 99%+ purity, QR-linked COA.
Important: This content is for informational and research purposes only and is not intended for human or veterinary use. Consult your physician for health-related guidance and laboratory monitoring.
How It Works
Identical to native GRF with hexarelin modification for extended half-life (25-30 min). Selectively mobilizes visceral fat through GH/IGF-I-mediated lipolysis.
Key Benefits
- ✓15-18% visceral fat reduction
- ✓33% hepatic steatosis reduction
- ✓Preserved subcutaneous fat
- ✓Improved liver enzymes (ALT/AST)
- ✓Lean mass gain 0.5-1.0 kg
Dosing Protocols
Beginner / Intermediate
Dose
1 mg
Frequency
Once daily subcutaneous, 5 days on / 2 off
Cycle Length
12 weeks
Notes
Start at 1 mg (range 1-2 mg) and titrate toward 2 mg as tolerated
Advanced
Dose
2 mg
Frequency
Once daily subcutaneous (evening)
Cycle Length
26 weeks
Notes
Can continue long-term; most studies show benefit at 26 weeks
Side Effects & Safety
Common Side Effects
- Injection site reactions (most common)
- Headache (10-20%)
- Flushing or water retention
- Carpal tunnel syndrome (1-2%, rare)
- Edema (peripheral, transient)
Contraindications
- Pregnancy and breastfeeding
- Active or recent cancer
- Untreated hypothyroidism
- Diabetic retinopathy
- Acute critical illness
- Closed epiphyses
Stacking & Synergies
These compounds have complementary mechanisms and may enhance results when used together.
Key Takeaway
FDA-approved visceral fat loss: Tesamorelin selectively targets dangerous belly fat with clinical proof.
Research Disclaimer: This content is for informational and research purposes only. It is not medical advice. These products are not approved by the FDA for human consumption. Consult a qualified healthcare provider before starting any new protocol. The information provided is based on preclinical research and anecdotal reports and has not been formally evaluated in randomized controlled trials.